Jardiance, a once-daily pill launched in 2014 by Eli Lilly and Co. and Boehringer Ingelheim, already was on pace to break $1 billion in sales this year. Now, with the latest news, it could get an ...

EMPEROR-Reduced met its primary endpoint, demonstrating superiority with Jardiance ® (empagliflozin) 10 mg compared to placebo in reducing the risk for the composite of cardiovascular death or ...

Heart failure and chronic kidney disease often go hand in hand. And when they do, the risk of death and hospitalization increase. A new analysis from Eli Lilly and Boehringer Ingelheim on their ...

Approval adds to the treatment options for the more than 35 million adults in the U.S. affected by chronic kidney disease (CKD) Jardiance ® (empagliflozin) 10 mg tablets significantly reduced the risk ...

JARDIANCE is not for use to lower blood sugar in adults with type 2 diabetes who have severe kidney problems, because it may not work. IMPORTANT SAFETY INFORMATION Do not take JARDIANCE if you are ...

Jardiance is a diabetes medication that manages blood glucose levels, it is also used as a weight loss treatment. The active drug, Empagliflozin, although not technically a weight loss medication, ...

Eli Lilly and Boehringer Ingelheim's Jardiance has been on a tear recently with an FDA fast track in heart failure and a key trial win in kidney disease. But when it comes to treating Type 1 diabetes, ...

RIDGEFIELD, Conn. and INDIANAPOLIS, March 12, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of Jardiance ® (empagliflozin) ...

The overall clinical benefit with Jardiance was consistent for those with either new or pre-existing heart failure, for those with or without diabetes and for those with either preserved or reduced ...

RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 13, 2019 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today results from the EMPERIAL-Reduced and EMPERIAL-Preserved ...

RIDGEFIELD, Conn. and INDIANAPOLIS, July 30, 2020 /PRNewswire/ -- Positive top-line results from the EMPEROR-Reduced phase III trial in adults with heart failure with reduced ejection fraction, with ...